Biological
LYB001
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
2
50%
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Other(4)
Detailed Status
unknown4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)
Trials by Status
unknown4100%
Recent Activity
0 active trials
Showing 4 of 4
unknownearly_phase_1
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
NCT05928455
unknownphase_2
The Phase Ⅱ/Ⅲ Trial of LYB001
NCT05602558
unknownphase_2
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
NCT05137444
unknownphase_1
A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001
NCT05125926
Clinical Trials (4)
Showing 4 of 4 trials
NCT05928455Early Phase 1
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
NCT05602558Phase 2
The Phase Ⅱ/Ⅲ Trial of LYB001
NCT05137444Phase 2
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
NCT05125926Phase 1
A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4